Wegovy's Real-World weight loss power tested in 500 korean patients
NCT ID NCT07280221
First seen Dec 18, 2025 · Last updated May 07, 2026 · Updated 15 times
Summary
This study follows 500 Korean adults with obesity who are starting Wegovy (semaglutide) as part of their normal care. Researchers will track weight changes and safety over about 52 weeks. The goal is to see how effective the medication is in real-world settings, not a controlled lab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Daejeon Endo Internal Medicine Clinic
Daejeon, 35220, South Korea
Conditions
Explore the condition pages connected to this study.